Core Viewpoint - Shen Guan Holdings (00829) reported a revenue of approximately 1.023 billion yuan for 2025, reflecting a year-on-year growth of 0.6%. However, the company experienced a significant loss attributable to shareholders of 69.773 million yuan, marking a shift from profit to loss compared to the previous year. The earnings per share were reported at a loss of 2.2 cents [2]. Financial Performance - Revenue for 2025 was approximately 1.023 billion yuan, with a year-on-year increase of 0.6% [2]. - The company reported a loss attributable to shareholders of 69.773 million yuan, indicating a transition from profit to loss [2]. - Earnings per share were recorded at a loss of 2.2 cents [2]. Profitability Metrics - The gross profit margin decreased from approximately 16.8% in the previous year to about 10.2% in the current year [2]. - When excluding inventory write-offs and provisions, the gross profit margin fell from 18.9% in the previous year to approximately 14.8% in the current year [2]. Operational Challenges - The decline in gross profit margin was attributed to an increase in inventory write-offs and provisions, as well as a significant rise in sales of six new product series, necessitating accelerated sales promotions for older products and those related to past new product trials [2].

Group 1 - MGM China (02282) announced the cancellation of 39,200 shares that have been repurchased, effective March 31, 2026 [2] - The stock price of MGM China showed a slight increase of 0.03, representing a change of 0.27% [1] - The trading volume for MGM China reached 210,000 shares at one point during the day [1] Group 2 - The stock price fluctuated between 10.88 and 11.20 during the trading session [1] - The daily price change percentages included 1.45%, 1.00%, and 0.45% at various intervals [1] - The trading activity peaked at 31,000 shares around 12:00/13:00 [1]

Core Viewpoint - The company, He Yu-B (02256), announced that its subsidiary, Shanghai He Yu Biomedical Technology Co., Ltd. ("He Yu Medicine"), has received FDA approval for the clinical trial application (IND) of its selective small molecule FGFR2/3 inhibitor, ABSK061, for treating children with achondroplasia (ACH) [1]. Group 1 - The IND approval from the FDA will facilitate the acceleration of ABSK061's overseas clinical development process [1]. - The drug has previously been granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) by the FDA, which supports its development in the pediatric rare disease space [1].

Core Viewpoint - The company has developed Irpagratinib, a highly selective oral small molecule FGFR4 inhibitor, which has shown promising safety, tolerability, and anti-tumor activity in clinical studies for advanced HCC patients with FGF19 overexpression [1][2] Group 1: Clinical Development - Irpagratinib is currently undergoing multiple clinical trials globally for advanced HCC patients with FGF19 overexpression, including combinations with various targeted immunotherapies for first-line treatment and as a monotherapy for second-line and later treatments [1] - The first patient dosing in the key registration clinical study for Irpagratinib was completed in June 2025, with the study covering over 50 research centers nationwide and progressing smoothly [1] Group 2: Regulatory Approvals - Irpagratinib has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for the treatment of HCC, which will support its clinical development, registration, and commercialization in Europe [2] - The drug has also previously obtained ODD and Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA), as well as Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA) in China [1]

Group 1 - The core viewpoint of the article highlights the significant stock transfer of FIH Mobile Limited (富智康集团) from Morgan Stanley to UBS Securities, amounting to HKD 10.093 billion, which represents 64.46% of the company's shares [2] - FIH Mobile Limited reported preliminary annual results for the year ending December 31, 2025, showing a revenue of USD 6.658 billion, reflecting a year-on-year increase of 16.74% [2] - The company achieved a net profit attributable to shareholders of USD 52.727 million, marking a turnaround from a loss to profit, with earnings per share of 6.7 cents [2] - A final dividend of 3.47 cents per share has been proposed by the company [2]

Group 1 - The core point of the article is that 瑞声科技 (AAC Technologies) announced a share buyback plan, intending to repurchase 450,000 shares at a cost of HKD 15.159 million [2] Group 2 - The share buyback is scheduled to take place on March 30, 2026 [2] - The current stock price of 瑞声科技 is HKD 33.10, reflecting a decrease of 0.68 or 2.01% [1]

Core Viewpoint - AAC Technologies (瑞声科技) announced a share buyback plan, indicating confidence in its financial position and future prospects [2] Group 1: Financial Actions - The company plans to repurchase 300,000 shares at a cost of HKD 9.96 million by March 31, 2026 [2] Group 2: Stock Performance - The stock price of AAC Technologies is currently at HKD 33.10, reflecting a decrease of 0.68 or 2.01% [1]

Group 1 - The company, Blue Moon Group (06993), announced a share buyback plan, intending to repurchase 11,000 shares at a cost of HKD 31 million by March 31, 2026 [1] - The stock price of Blue Moon Group showed a slight increase of 1.41% [1] - The trading volume during the specified time frame reached a peak of 230,000 shares [1] Group 2 - The company's stock price fluctuated between HKD 2.79 and HKD 2.89 during the trading session [1] - The announcement of the buyback reflects the company's strategy to enhance shareholder value [1] - The buyback is part of a broader trend among companies to return capital to shareholders amid market conditions [1]

Core Insights - The company reported a revenue of $257 million for the year ending December 31, 2025, representing a year-on-year growth of 0.7% [2] - The profit attributable to shareholders was $6.793 million, showing a significant increase of 758.8% compared to the previous year [2] - Basic earnings per share were reported at $0.0034 [2] Revenue Breakdown - Revenue from North America and Europe experienced a slight decline, primarily due to a decrease in earnings from drug discovery services [2] - The decline in North American and European revenue was attributed to pharmaceutical and biotechnology companies optimizing their R&D portfolios and cautiously controlling development expenditures [2] - Strong demand for laboratory testing services partially offset the revenue decline in these regions [2] Growth in China - Revenue growth in China was driven by improved capacity utilization and the company's marketing efforts [2]

Core Viewpoint - Hengding Industrial (01393) reported a decline in revenue and an increase in losses for the fiscal year 2025, indicating ongoing challenges in the coal market, particularly in coking coal demand and pricing pressure [2]. Financial Performance - The company's revenue for 2025 was approximately 1.939 billion yuan, representing a year-on-year decrease of 10.8% [2]. - The attributable loss to shareholders was about 623 million yuan, which is a slight reduction of 1.8% compared to the previous year [2]. - Basic loss per share was reported at 13.53 cents [2]. Sales and Pricing - The sales volume of premium coal reached approximately 1.598 million tons, showing a year-on-year increase of about 23.3% [2]. - Despite the increase in sales volume, the average selling price of premium coal fell from approximately 1,554.3 yuan per ton in 2024 to about 1,111.6 yuan per ton in the current year, marking a decline of approximately 28.5% [2].